Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenzhen's HEC Pharm Invests in US Novel Imaging Contrast Company

publication date: Jan 9, 2018

East Sunshine Foresight Fund, the venture capital arm of Shenzhen's HEC Pharm, will make a "series of investments" of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents. Enlyton combines antibodies with contrast agents to produce tumor images that are more precise. Its lead product is ENL210, a bioengineered anti-TAG-72 (tumor-associated glycoprotein) antibody fragment labeled with iodine-123. The product targets a broad family of solid tumors known as adenocarcinomas. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital